MedTrace Logo

Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults

NCT07215520 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2025-11-06

No results posted yet for this study

Summary

A Double-blind, Randomized, Controlled, Phase 2a Study to Evaluate the Safety and Tolerability of a Newcastle Disease Virus-based Mucosal Vaccine (NDV-HXP-S-KP.2) Relative to an Approved Systemic mRNA Vaccine in Previously Vaccinated Adults

Conditions

Interventions

BIOLOGICAL

NDV-HXP-S-KP.2

Nasal Administration of a COVID-19 vaccine to compare against a commercially available mRNA vaccine

BIOLOGICAL

COVID-19 mRNA Vaccine

Used as a comparator to study vaccine

Sponsors & Collaborators

  • CastleVax Inc.

    lead INDUSTRY

Principal Investigators

  • Michael Egan, PhD · CastleVax Inc.

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-11-03
Primary Completion
2026-08-19
Completion
2026-08-19
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07215520 on ClinicalTrials.gov